findmyKOL
Clinical trialNCT02650752CompletedPhase 1Interventional

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

SponsorMemorial Sloan Kettering Cancer CenterEnrollment11Central Nervous System (CNS) MetastasesMetastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal disease).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Michigan Health System

    Ann Arbor, Michigan, United States

  • Memoral Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, United States

  • Queens Cancer Center of Queens Hospital

    Jamaica, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lapatinib in Tandem With Capecitabine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Jan 2016
Primary completion
22 Jan 2021
Completion
22 Jan 2021
Last update posted
26 Jan 2021
Registered enrollment
11
Registry id
NCT02650752
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.